Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/21
End: 08/31/22
Due: 08/31/23
Phase: N/A
Priority: Normal
Start: 11/30/15
End: 11/30/23
Due: 11/30/24
Phase: N/A
Priority: Normal
Start: 08/01/22
End: 09/01/26
Due: 09/01/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies | NCT04773327 | Xiaohua Wu MD | user2@example.com | None | 2021-05-31 | 2022-08-31 | 2023-08-31 | - | - | 2025-07-14 |
| Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer | NCT02562365 | Xiaohua Wu MD | user2@example.com | None | 2015-11-30 | 2023-11-30 | 2024-11-30 | - | - | 2025-07-14 |
| Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | NCT05479487 | Xiaohua Wu MD | user2@example.com | None | 2022-08-01 | 2026-09-01 | 2027-09-01 | - | - | 2025-07-14 |